Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zevalin ibritumomab tiuxetan: Phase III data

In the international, open-label Phase III FIT trial in 414 patients who achieved partial or complete remission

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE